Nephros, Inc. (NEPH)
Healthcare · NCM
Price as at 30 Sept 2026, 21:45 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Nephros, Inc. trades at $3.71, which is 63% above the $1.36 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 47 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 48.4 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
NEPH dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
NEPH earnings and analyst estimates
Recommendation mix, 3 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Nephros, Inc.
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems. It markets its products to food service and hospitality sectors including quick-service restaurants, convenience stores, and restaurants. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
NEPH passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
2 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$276.7K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$103.7K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
NEPH peers
The largest companies in the same industry (Medical Instruments & Supplies), then in the same sector.
- MDLN Medline Inc.
- RSMDF ResMed Inc.
- SRT3.DE Sartorius Aktiengesellschaft
- SOLV Solventum Corporation
- BAX Baxter International Inc.
- RGEN Repligen Corporation
- AVTR Avantor, Inc.
- TFX Teleflex Incorporated
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Nephros, Inc. (NEPH) undervalued?
Against our fair value estimate of $1.36, NEPH at $3.71 is 63% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own NEPH?
2 of the institutions we track reported a position in NEPH in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is NEPH's P/E ratio?
NEPH trades at 48.4 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its NEPH data?
Fundamentals for NEPH come from company filings and exchange data, as listed on NCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:45 UTC and is delayed. Our data quality score for this company is 96/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for NEPH, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.